Breast cancer (BC) is an aggressive malignant disease in women worldwide with a high tendency to metastasize. However, important biomarkers for BC metastasis remain largely undefined. In the present study, we identified that long non-coding RNA-CTD-2108O9.1 is downregulated in BC tissues and cells and acts as a metastatic inhibitor of BC. Mechanistic investigation determined that lncRNA-CTD-2108O9.1 represses metastasis by targeting leukemia inhibitory factor receptor (LIFR), which is designated as a metastasis suppressor in BC. Our study characterizes a significant tumor suppressor active in BC metastasis repression through the known metastasis inhibitor LIFR.
development and drug resistance by heterogeneous nuclear ribonucleoprotein L protein. 11 Overexpressed colorectal cancerassociated lncRNA (CCAL) in colorectal cancers was shown to activate Wnt/b-catenin-mediated cancerous progression and indicates poor prognosis. 12 Another novel lncRNA, lncRNA-CTD-2108O9.1, is downregulated in gastric cancer (GC) and its expression level was related to leukemia inhibitory factor receptor (LIFR) in GC. 13 LIFR, the receptor of leukemia inhibitory factor (LIF), has been reported to be a metastatic suppressor in BC. 14 However, the molecular mechanism of how lncRNAs affect LIFR is unclear.
In the present study, we examined lncRNA-CTD-2108O9. medium with 10% FBS using impermeable flasks, and MCF-10A cells were cultured in DMEM/F12 medium with 5% horse serum, 100 ng/mL cholera, 10 lg/mL insulin, 20 ng/mL epidermal growth factor (EGF) toxin and 500 ng/mL hydrocortisone. All cells were cultured in a humidified incubator at 37°C with 5% CO 2 (Thermo Fisher Scientific, Waltham, MA, USA).
| Human tissue samples and ethical approval
Ninety-seven BC tissues were obtained from patients who underwent modified radical mastectomy after being diagnosed with BC at the
Department of Breast Surgery in the First Affiliated Hospital of China
Medical University. Tissues were collected within a half hour following surgery, frozen in liquid nitrogen overnight, and kept at À80°C for long-term storage. All patients signed an ethical consent form. 
| RNA isolation and quantitative real-time PCR

| Vectors and transfections
Vectors were transfected to cells with Lipofectamine 2000 Reagent (Invitrogen). According to the product manuals and cellular tolerance, a final concentration of 1.75 lg/mL plasmid or siRNA was used for each transfection in 25 mL impermeable culture flasks (Corning, Corning, NY, USA) with 2 mL culture medium. After 6-hour coculture with vectors, the culture medium was thoroughly exchanged.
After lentivirus transfection, stable cells were selected and constructed by puromycin.
| Migration and invasion assays
Transwell migration assays were carried out with transwells (Corning) and matrigel invasion assays were carried out with matrigel (BD Biosciences, San Jose, CA, USA). Two days after transfection, 2.5 9 10 5 cells were planted into the upper chamber of the well in 0.2 mL medium with no FBS, and 0.6 mL medium with 10% FBS was added to the lower chamber. After 24 hours, cells were stained with H&E, and the quantity of cells capable of passing through the membrane and matrigel were calculated from 10 random areas across the visual field with a Leica DMI300 microscope (Leica, Wetzlar, Germany).
| Scratch wound healing assay
Scratch wound healing assays were carried out 24 hours after transfection. Cells were seeded in 6-well plates and incubated for 24 hours. The monolayer was then scratched with a sterile pipette tip and the wound area monitored with a light microscope (DMI3000B; Leica, Bannockburn, IL, USA) at 0, 6, 12, and 24 hours after wounding. Images were analyzed with Image-J software (Media Cybernetics) and ratios were calculated according to the formula
| Cell proliferation assay
Proliferative ability was detected using a CCK-8 (Dojindo Laboratories, Tokyo, Japan) following the manufacturer's instructions. Cells were plated in a 96-well plate at 2500 cells per well and tested at 450 nm wavelength with a microplate reader (Bio-Rad, Hercules, CA, USA). Figure S1 ). Figure S2A . We then analyzed the correlation between them and found that laminin (r = .488, P < .01) and b-catenin (r = .334, P < .01) were moderately correlated to lncRNA-CTD-2108O9.1 in BC tissues, whereas snail (r = .282, P < .05), N-cadherin (r = .261, P < .05) and twist (r = .244, P < .05) were weakly related with lncRNA-CTD-2108O9.1 (Table 2 ).
| Western blotting analysis
3.5 | Coordinated expression of lncRNA-CTD-
2108O9.1 and LIFR in BC tissues and cells
We examined the expression of LIFR relative to lncRNA-CTD-2108O9.1 by real-time PCR and found that LIFR transcript levels were downregulated in 97 cases of BC patient tissue samples (Figure 5A) . Thus, correlation between lncRNA-CTD-2108O9.1 and LIFR RNA expression levels was analyzed. We found that correlation coefficient was 0.393 (P < .01) ( Figure S2C ), suggesting a moderate relevance between lncRNA-CTD-2108O9.1 and LIFR RNA expression levels, although their overall expression trends were similar. lncRNA, long non-coding RNA. *P < .05, **P < .01. In addition to their dysregulated expression and clinical associations, the involvement of lncRNAs in cancer initiation, progression, and prognosis has been eagerly studied. [20] [21] [22] Examples include lncRNA MRCCAT1 (metastatic renal cell carcinoma-associated transcript 1) expression being raised in metastatic foci with the ability to strengthen metastasis in clear cell renal cell carcinoma 23 and the high expression of lncRNA CRNDE (colorectal neoplasia differentially expressed) associated with enlarged tumor size, advanced pathological stages, and reinforcing apoptotic and proliferative capacity in colorectal cancer. 24 In the present study, we overexpressed and The regulation patterns and mechanisms by which lncRNAs act on cancer are numerous and complicated. Some lncRNAs occupy binding sites of RNAs and proteins, serving as decoys. 25 Some associate with protein factors to activate transcription and chromatin regulation, acting as enhancers. 26 Others act as scaffolds to modulate interactions between proteins and genes, thus affecting transcription of oncogenes or anti-oncogenes. 27 Antisense lncRNA (aslncRNA) are a special type of lncRNA reported to interfere with proximal genes through cis-acting effects to regulate transcription and post-transcriptional modifications. 28, 29 LncRNA-CTD-2108O9.1, also called EGFLAM-AS1 and located in the chromosome 5p13.1 region, is the antisense of the EGFLAM gene. However, studies on EGFLAM mainly show its function on visual perception, seldom on the oncological procedure. 30 We were attracted to another gene, LIFR, which is also in the chromosome 5p13.1 region, within 50 kbp downstream of lncRNA-CTD-2108O9.1.
LIFR is the receptor of LIF, which serves as a cytokine complex with oncostatin M. 31 Interestingly, LIFR is downregulated and regarded as a tumor suppressor gene in gastric cancers, hepatocellular carcinoma, breast cancer, pancreatic cancers and colorectal carcinoma. In conclusion, to the best of our knowledge, our study is the first to explore which transcript mediates LIFR and inhibits metastasis at the lncRNA level ( Figure 8 ). We validated the reduced expression of lncRNA-CTD-2108O9.1 in BC and its inhibitory effects on metasta- 
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